Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Change in Acquisitions & Divestments (2022 - 2025)

Historic Change in Acquisitions & Divestments for Zentalis Pharmaceuticals (ZNTL) over the last 4 years, with Q3 2025 value amounting to $60.0 million.

  • Zentalis Pharmaceuticals' Change in Acquisitions & Divestments fell 1891.89% to $60.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $261.5 million, marking a year-over-year increase of 303.39%. This contributed to the annual value of $271.2 million for FY2024, which is 4632.97% down from last year.
  • According to the latest figures from Q3 2025, Zentalis Pharmaceuticals' Change in Acquisitions & Divestments is $60.0 million, which was down 1891.89% from $70.0 million recorded in Q2 2025.
  • Zentalis Pharmaceuticals' 5-year Change in Acquisitions & Divestments high stood at $198.5 million for Q2 2023, and its period low was $54.0 million during Q2 2024.
  • In the last 4 years, Zentalis Pharmaceuticals' Change in Acquisitions & Divestments had a median value of $71.7 million in 2024 and averaged $92.5 million.
  • Its Change in Acquisitions & Divestments has fluctuated over the past 5 years, first skyrocketed by 25125.13% in 2023, then plummeted by 7279.01% in 2024.
  • Zentalis Pharmaceuticals' Change in Acquisitions & Divestments (Quarter) stood at $114.2 million in 2022, then plummeted by 52.65% to $54.1 million in 2023, then surged by 32.16% to $71.5 million in 2024, then fell by 16.08% to $60.0 million in 2025.
  • Its last three reported values are $60.0 million in Q3 2025, $70.0 million for Q2 2025, and $60.0 million during Q1 2025.